

2 December 2024 15:05 GMT

BLOCK LISTING SIX MONTHLY RETURN

INFORMATION PROVIDED ON THIS FORM MUST BE TYPED OR PRINTED ELECTRONICALLY AND PROVIDED TO AN *RIS*.

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 2 December 2024

| | | | | |
|--|-------|---|-----|---------------------|
| Name of <i>applicant</i> : | | ASTRAZENECA PLC | | |
| Name of scheme: | | ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL- EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME | | |
| Period of return: | From: | 1 JUNE 2024 | To: | 30 NOVEMBER 2024 |
| Balance of unallotted securities under scheme(s) from previous return: | | 4,090,043 | | |
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | | 0 | | |
| Less: Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G): | | 60,887 | | |
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | | 4,029,156 | | |

| | |
|------------------------------|---------------------|
| Name of contact: | Hannah Tattersall |
| Telephone number of contact: | +44 (0)20 3749 5000 |

[AstraZeneca](#)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media [@AstraZeneca](#)

Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRFSUSAEELSELE